Moderna recently announced that Arpa Garay will join the company as chief commercial officer, effective May 31, 2022.
Garay joins Modera from Merck & Co, where she became an expert in oncology,...
GSK recently entered into a $1.9 billion agreement to acquire biopharmaceutical company Sierra Oncology to treat rare cancers.
Myelofibrosis is a rare blood cancer that causes considerable...
The FDA recently granted priority review for AstraZeneca's Enhertu to treat adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 mutation and...
Sanofi recently announced positive results from the Phase 1/2 clinical trial evaluating its Bruton's tyrosine kinase (BTK) inhibitor, rilzabrutinib, in adults with heavily pre-treated immune...
FDA recently lifted the partial hold placed on clinical trials evaluating Gilead’s magrolimab combined with azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...
Eli Lilly & Company recently announced updates on the Phase 2 clinical trial studying its kinase inhibitor, Retevmo, in RET fusion-positive non-small cell lung cancer (NSCLC).
The...
Pfizer will acquire clinical-stage biopharmaceutical company ReViral to discover, develop, and commercialize novel antiviral respiratory syncytial virus (RSV) therapeutics.
ReViral’s...
Blue Care Network recently announced the launch of Michigan’s first end-to-end pharmacogenomics precision medicine program, Blue Cross Personalized Medicine. This program leverages genetic...
FDA recently approved ViiV Healthcare’s fixed-dose combination of abacavir, dolutegravir, and lamivudine to treat pediatric patients with HIV-1.
The agency also approved the...
Sandoz recently expanded its strategic collaboration agreement with Ares Genetics (Ares) to drive cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
The...
Merck recently reaffirmed its commitment to enable broad equitable access to its human papillomavirus (HPV) vaccines.
Under the initiative, Merck will expand its vaccines manufacturing facility...
Roche recently announced that its monoclonal IgG1 antibody, tiragolumab, plus Tecentriq and chemotherapy, did not meet its co-primary endpoints in a Phase 3 extensive-stage small cell lung cancer...
FDA recently expanded the indication of the long-acting injectable HIV regimen, Cabenuva, to include virologically suppressed adolescents 12 years of age and older.
Johnson & Johnson and...
AstraZeneca recently announced that it will present new data underscoring its oncology treatment landscape through diverse early pipelines and novel drug combinations.
The company’s next...
Gilead recently announced $24 million in grants to reduce health disparities, improve access to quality healthcare, advance medical education, and support local communities most impacted by the HIV and...
Merck recently announced that its cytomegalovirus (CMV) treatment, Prevymis (letermovir), lowered the odds of CMV reactivation by 88% 100 days after allogeneic hematopoietic cell transplantation...
Pfizer recently announced positive top-line results from a second Phase 3 study of its selective sphingosine 1-phosphate (S1P) receptor modulator, etrasimod, to treat moderately to severely active...
FDA recently issued a complete response letter (CRL) for Eli Lilly and Company’s biologics license application (BLA) for its combination antibody therapy, sintilimab, to treat nonsquamous...
FDA recently approved Bristol Myers Squibb’s antibody combination, Opdualag (nivolumab and relatimab-rmbw), for adult and pediatric patients 12 years of age and older with unresectable or...
Johnson & Johnson recently announced a series of initiatives in high tuberculosis (TB) burden countries to empower a generation of youth to end TB and increase disease detection.
The...
